119 Recruiting Myelodysplastic Syndromes Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Myelodysplastic Syndromes
Related Conditions
Top Recruiting Myelodysplastic Syndromes Studies
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
📍 Local Institution - 0070 — Clovis, California
View Study & Checklist ➔Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
📍 Innovative Clinical Research Institute Whittier — Lakewood, California
View Study & Checklist ➔Inqovi Maintenance Therapy in Myeloid Neoplasms
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
📍 Local Institution - 0137 — Miami, Florida
View Study & Checklist ➔A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
📍 Local Institution - 0051 — Los Alamitos, California
View Study & Checklist ➔Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
📍 Oregon Health Sciences University — Portland, Oregon
View Study & Checklist ➔Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
📍 Local Institution - 107 — Berkeley, California
View Study & Checklist ➔A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Ascorbate in Myelodysplastic Syndrome
📍 University of Iowa — Iowa City, Iowa
View Study & Checklist ➔A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
📍 Genesis Cancer and Blood Institute — Hot Springs, Arkansas
View Study & Checklist ➔Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
📍 West Virginia University Cancer Institute — Morgantown, West Virginia
View Study & Checklist ➔A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
📍 Keck School of Medicine of USC — Los Angeles, California
View Study & Checklist ➔Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
📍 CancerCare Manitoba — Winnipeg, Manitoba
View Study & Checklist ➔Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
📍 Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
📍 University of California Davis Health (UC Davis Health) — Sacramento, California
View Study & Checklist ➔A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
📍 Mayo Clinic — Jacksonville, Florida
View Study & Checklist ➔Study of REM-422 in Patients With AML or Higher Risk MDS
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
📍 H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
View Study & Checklist ➔Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
📍 University of Miami — Miami, Florida
View Study & Checklist ➔A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
📍 GSK Investigational Site — Goodyear, Arizona
View Study & Checklist ➔